French pharmaceutical company Sanofi declared in a statement on September 14 that its type 2 diabetes medication has showed promising results during its final clinical trial. If the drug, called LixiLan, will be passing the regulatory reviews of the health officials, it will become available in drugstores across the United States and European Union starting the first quarter of 2016.
LixiLan-L was the name of the drug used in the final clinical trial from Sanofi. Before it, LixiLan-O, the first version of the drug, also showed promising results back in July 2016.
LixiLan comes in the form of an injectable drug. Its chemical configuration was achieve by combining insuline glargine and lixisenatide. While both substances are known as cause-to-action medication for type 2 diabetes, Sanofi is the first drug manufacturer that successfully merged together the two substances. The insuline glargine is produced by the company itself, whereas the lixisenatide is supplied by Zealand Pharma.
By combining the two drugs and injecting the preparation in the human physique, the levels of blood glucose will exhibit a significant reduction. The decline isn’t nearly as drastic when taking the insuline glargine alone. The only problem with the LixiLand is that the side effects list has doubled, considering is a combination of both insuline and lixisenatide.
Thanks to the findings of the pharmaceutical company, new treatment choices may now be given to the patients that are unable to maintain their HbA1c levels. The clinical trial examined an important use of investigational medicine. Richard M. Bergenstal, director of the US International Diabetes Center, Minnesota said that more than half of the patients who are under basic insulin treatments no longer respond to the medication, and that the significance of this study and finding will prove essential to type 2 diabetes treatment.
In the clinical trial, 730 participants that were diagnosed with type 2 diabetes that does not respond to any insulin treatment were subjected to a half an year study which tested tested the efficiency of the combined drug, as well as its safety, compared to taking Lantus alone. The patients who took meltformin, a drug that is generally prescribed to type 2 diabetes and is used in combination with insulin, were asked to continue their treatment during the entire span of the study.
I think it is beyond doubt that Sanofi was able to prove the efficacy of their HbA1c decreasing drug. LixiLan successfully reduced the levels of HbA1c of all the type 2 diabetes within 30 weeks, regardless of what other medication the participants tried during the trials.
Photo Credits pixabay